Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Company profile
Ticker
MYOV
Exchange
Website
CEO
Lynn Seely
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Myovant Sciences, Inc. • Myovant Holdings Ltd. • Myovant Sciences GmbH • Myovant Sciences Ireland Limited • Myovant Treasury, Inc. • Myovant Treasury Holdings, Inc. ...
MYOV stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
20 Mar 23
EFFECT
Notice of effectiveness
17 Mar 23
EFFECT
Notice of effectiveness
17 Mar 23
25-NSE
Exchange delisting
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
Transcripts
MYOV
Earnings call transcript
2022 Q1
28 Jul 22
MYOV
Earnings call transcript
2021 Q4
10 May 22
MYOV
Earnings call transcript
2021 Q3
26 Jan 22
MYOV
Earnings call transcript
2021 Q2
26 Oct 21
MYOV
Earnings call transcript
2021 Q1
28 Jul 21
MYOV
Earnings call transcript
2020 Q4
11 May 21
MYOV
Earnings call transcript
2020 Q3
11 Feb 21
MYOV
Earnings call transcript
2020 Q2
12 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 256.76 mm | 256.76 mm | 256.76 mm | 256.76 mm | 256.76 mm | 256.76 mm |
Cash burn (monthly) | 32.02 mm | 17.59 mm | 18.81 mm | 13.52 mm | 34.30 mm | 22.49 mm |
Cash used (since last report) | 507.37 mm | 278.69 mm | 297.98 mm | 214.28 mm | 543.42 mm | 356.31 mm |
Cash remaining | -250.61 mm | -21.94 mm | -41.22 mm | 42.48 mm | -286.66 mm | -99.55 mm |
Runway (months of cash) | -7.8 | -1.2 | -2.2 | 3.1 | -8.4 | -4.4 |
Institutional ownership, Q2 2023
53.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 51.67 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sumitomo Chemical | 45.80 mm | $0.00 |
BBBOF BB Biotech | 5.87 mm | $0.00 |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Mar 23 | Sumitomo Chemical | Common Shares | Buy | Acquire P | Yes | No | 27 | 51,599,200 | 1.39 bn | 45,798,176 |
10 Mar 23 | Arjona Ferreira Juan Camilo | Common Shares | Sale back to company | Dispose D | No | No | 0 | 160,082 | 0.00 | 0 |
10 Mar 23 | Arjona Ferreira Juan Camilo | Common Shares | Sale back to company | Dispose D | No | No | 0 | 86,602 | 0.00 | 160,082 |
10 Mar 23 | Arjona Ferreira Juan Camilo | Performance Stock Unit Common Shares | Sale back to company | Dispose D | No | No | 0 | 103,703 | 0.00 | 0 |
10 Mar 23 | Arjona Ferreira Juan Camilo | Stock Options Common Shares | Sale back to company | Dispose D | No | No | 17.88 | 79,472 | 1.42 mm | 0 |
10 Mar 23 | Arjona Ferreira Juan Camilo | Stock Options Common Shares | Sale back to company | Dispose D | No | No | 8.08 | 134,464 | 1.09 mm | 0 |
10 Mar 23 | Arjona Ferreira Juan Camilo | Stock Options Common Shares | Sale back to company | Dispose D | No | No | 7.78 | 65,863 | 512.41 k | 0 |
10 Mar 23 | Arjona Ferreira Juan Camilo | Stock Options Common Shares | Sale back to company | Dispose D | No | No | 7.78 | 63,717 | 495.72 k | 0 |
10 Mar 23 | Arjona Ferreira Juan Camilo | Stock Options Common Shares | Sale back to company | Dispose D | No | No | 7.78 | 155,300 | 1.21 mm | 0 |
10 Mar 23 | Guinan Mark | Common Shares | Sale back to company | Dispose D | No | No | 0 | 3,673 | 0.00 | 0 |